Calquence (acalabrutinib) is a brand-name drug that’s prescribed for certain types of blood cancer in adults, including some lymphomas. Calquence comes as an oral tablet that’s typically taken twice ...

Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of hematology research ...

British drug giant AstraZeneca is rushing forward a big clinical trial for its blood cancer drug Calquence because it has shown early promising results in later-stage COVID-19 patients—those in ...

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax ...

Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed. Calquence (acalabrutinib) led to fewer ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE® (acalabrutinib) in ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ASCEND Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) maintained a statistically significant progression-free survival ...

Please provide your email address to receive an email when new articles are posted on . The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with ...

Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma. Calquence (acalabrutinib) plus standard-of-care ...

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE ...